ADMA Biologics Inc
NASDAQ:ADMA

Watchlist Manager
ADMA Biologics Inc Logo
ADMA Biologics Inc
NASDAQ:ADMA
Watchlist
Price: 15.9 USD -1.12% Market Closed
Market Cap: 3.8B USD
Have any thoughts about
ADMA Biologics Inc?
Write Note

P/E
Price to Earnings

55.2
Current
-7.7
Median
22.3
Industry
Higher than median
Higher than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
55.2
=
Market Cap
3.8B USD
/
Net Income
68.1m USD
All Countries
Close
Market Cap P/E
US
ADMA Biologics Inc
NASDAQ:ADMA
3.8B USD 55.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -179 740.6
US
Abbvie Inc
NYSE:ABBV
340.8B USD 67.1
US
Amgen Inc
NASDAQ:AMGN
156.4B USD 38.2
US
Gilead Sciences Inc
NASDAQ:GILD
129.7B USD 270.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.9B USD -220.2
US
Epizyme Inc
F:EPE
94.1B EUR -475.4
AU
CSL Ltd
ASX:CSL
124.4B AUD 29.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.8B USD 16.7
US
Seagen Inc
F:SGT
39.3B EUR -55
NL
argenx SE
XBRU:ARGX
36.3B EUR -337.7
Earnings Growth PEG
US
ADMA Biologics Inc
NASDAQ:ADMA
Average P/E: 79.5
55.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -179 740.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
67.1
73%
0.9
US
Amgen Inc
NASDAQ:AMGN
38.2
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
270.2
184%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -220.2 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -475.4 N/A N/A
AU
CSL Ltd
ASX:CSL
29.9
18%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
12%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -55 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -337.7 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
30.3
2-Years Forward
P/E
22.5
3-Years Forward
P/E
16.9